STAT3 and cholangiocarcinoma: The authors demonstrated that sorafenib induces STAT3 dephosphorylation by stimulating phosphatase SHP2 activity, sensitizes CC cells to TRAIL-mediated apoptosis, and is therapeutic in a syngeneic rat, orthotopic CC model that mimics human disease [22].